These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10750446)

  • 1. Assessing allocation concealment and blinding in randomized controlled trials: why bother?
    Schulz KF
    ACP J Club; 2000; 132(2):A11-2. PubMed ID: 10750446
    [No Abstract]   [Full Text] [Related]  

  • 2. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking.
    Viera AJ; Bangdiwala SI
    Fam Med; 2007 Feb; 39(2):132-7. PubMed ID: 17273956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing allocation concealment and blinding in randomised controlled trials: why bother?
    Schulz KF
    Evid Based Nurs; 2001 Jan; 4(1):4-6. PubMed ID: 11707879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing allocation concealment and blinding in randomised controlled trials: why bother?
    Schulz KF
    Equine Vet J; 2005 Sep; 37(5):394-5. PubMed ID: 16163939
    [No Abstract]   [Full Text] [Related]  

  • 5. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
    Haahr MT; Hróbjartsson A
    Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials.
    Pildal J; Hróbjartsson A; Jørgensen KJ; Hilden J; Altman DG; Gøtzsche PC
    Int J Epidemiol; 2007 Aug; 36(4):847-57. PubMed ID: 17517809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The blind leading the blind: use and misuse of blinding in randomized controlled trials.
    Miller LE; Stewart ME
    Contemp Clin Trials; 2011 Mar; 32(2):240-3. PubMed ID: 21070890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Roaming through methodology. XXIII. The need for randomization and blinding in therapeutic investigations].
    Knipschild PG
    Ned Tijdschr Geneeskd; 2000 Sep; 144(38):1826-8. PubMed ID: 11020835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods.
    Devereaux PJ; Choi PT; El-Dika S; Bhandari M; Montori VM; Schünemann HJ; Garg AX; Busse JW; Heels-Ansdell D; Ghali WA; Manns BJ; Guyatt GH
    J Clin Epidemiol; 2004 Dec; 57(12):1232-6. PubMed ID: 15617948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of blinding in randomized controlled trials found results inconsistent and questionable.
    Boutron I; Estellat C; Ravaud P
    J Clin Epidemiol; 2005 Dec; 58(12):1220-6. PubMed ID: 16291465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study.
    Herbison P; Hay-Smith J; Gillespie WJ
    J Clin Epidemiol; 2011 Oct; 64(10):1070-5. PubMed ID: 21474279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.
    Hróbjartsson A; Forfang E; Haahr MT; Als-Nielsen B; Brorson S
    Int J Epidemiol; 2007 Jun; 36(3):654-63. PubMed ID: 17440024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Funding, disease area, and internal validity of hepatobiliary randomized clinical trials.
    Kjaergard LL; Gluud C
    Am J Gastroenterol; 2002 Nov; 97(11):2708-13. PubMed ID: 12425537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals.
    Hewitt C; Hahn S; Torgerson DJ; Watson J; Bland JM
    BMJ; 2005 May; 330(7499):1057-8. PubMed ID: 15760970
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlled trials: allocation concealment, random allocation, and blinding.
    Sedgwick P
    BMJ; 2015 May; 350():h2633. PubMed ID: 25979365
    [No Abstract]   [Full Text] [Related]  

  • 16. Planning of clinical trials.
    Boissel JP
    J Intern Med; 2004 Apr; 255(4):427-38. PubMed ID: 15049877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial.
    Piaggio G; Elbourne D; Schulz KF; Villar J; Pinol AP; Gülmezoglu AM;
    BMC Med Res Methodol; 2003 Oct; 3():19. PubMed ID: 14525622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintaining allocation concealment: following your SNOSE.
    Scales DC; Adhikari NK
    J Crit Care; 2005 Jun; 20(2):191-3. PubMed ID: 16139164
    [No Abstract]   [Full Text] [Related]  

  • 19. The expression of the allocation concealment for randomised controlled trials needs to be improved.
    Zhao X; Yan SG
    Injury; 2011 Apr; 42(4):430-1; author reply 431. PubMed ID: 21145543
    [No Abstract]   [Full Text] [Related]  

  • 20. [Critical analysis of a parallel group randomized trial].
    Giraudeau B
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 1):261-7. PubMed ID: 12486375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.